SUPN Form 144 shows 59,900-share sale after option exercise
Rhea-AI Filing Summary
Supernus Pharmaceuticals (SUPN) notice reports a proposed sale of 59,900 common shares, with an aggregate market value of $2,875,200, to be sold on or about 10/09/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The shares were acquired the same day by exercise of stock options and paid in cash. The filer also disclosed multiple prior 10b5-1 plan sales across August–October 2025 totaling substantial proceeds (individual trades range from $45,001 to $2,558,888.12), showing ongoing systematic insider selling. The filer affirms no undisclosed material nonpublic information and provides standard Rule 144 representations.
Positive
- Securities acquired by exercise of options and paid in cash, indicating no contingent consideration
- Sales executed under 10b5-1 plans, which are pre‑arranged and reduce timing uncertainty about insider intent
Negative
- Substantial recent insider sales across Aug–Oct 2025 with large gross proceeds (multiple trades above $1M)
- Proposed sale on 10/09/2025 adds incremental supply equal to 59,900 shares (~0.11% of outstanding), potentially pressuring short-term liquidity
Insights
TL;DR: A near-term insider sale of 59,900 shares follows option exercise and ongoing 10b5-1 sales.
The transaction shows the filer exercised options 10/09/2025 and intends to sell 59,900 shares through Morgan Stanley, generating an indicated market value of $2,875,200. The filing lists many 10b5-1 sales from 08/06/2025 through 10/02/2025, with individual gross proceeds up to $2.56M.
This pattern indicates planned liquidity events rather than ad-hoc disposals; monitor near-term total insider sell volume relative to the company’s outstanding shares (56,073,088) over the next few weeks for potential market supply effects.
TL;DR: The sale size is modest relative to shares outstanding but could add short-term supply pressure on trading days around 10/09/2025.
The proposed sale equals roughly 0.11% of the disclosed 56,073,088 shares outstanding, which is small in isolation. However, cumulative 10b5-1 sales listed (multiple trades across months) represent larger absolute proceeds and could affect intraday liquidity on sales dates.
Watch trading volume on 10/09/2025 and nearby sessions to see if the disclosed sales coincide with higher-than-normal supply; such effects typically appear within days of executed filings.